Summary:
The purpose of this study is to assess the safety and efficacy of MK-3102 compared to placebo in participants with inadequate glycemic control on metformin monotherapy. The primary hypothesis is that after 24 weeks, the addition of treatment with MK-3102 provides greater reduction in hemoglobin A1c (A1C) than placebo.
Qualified Participants Must:
• Be 18 years of age, or older
•
Be taking Metformin only with a dose of 1500mg or higher
Qualified Participants May Receive:
Investigational medication for Diabetes
and compensation for time and travel.